Last update Feb. 6, 2022
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Tiagabine Hydrochloride in other languages or writings:
Main tradenames from several countries containing Tiagabine Hydrochloride in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 90 | % |
Molecular weight | 412 | daltons |
Protein Binding | 96 | % |
VD | 1 - 1.3 | l/Kg |
pKa | 4.14 | - |
Tmax | 1 | hours |
T½ | 7 - 9 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Anticonvulsant indicated in the treatment of epilepsy. Oral administration in one or two daily doses.
Since the last update we have not found published data on its excretion in breastmilk.
Their very high percentage of protein binding and large volume of distribution (Jacob 2016) make it highly unlikely that significant quantities will pass into breast milk.
No problems were reported in two infants whose mothers were taking it. (Tomson 2007, Neppe 2000)
Expert authors consider the use of monoclonal antibodies to be safe or very probably safe during breastfeeding. (Cabo 2019, Davanzo 2013)
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable (Bar-Oz 2000), especially during the neonatal period and in the event of prematurity.